These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 34186160)
21. The role of ASXL1 in hematopoiesis and myeloid malignancies. Asada S; Fujino T; Goyama S; Kitamura T Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018 [TBL] [Abstract][Full Text] [Related]
22. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1. Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor H; Meiners MJ; Cheek MA; Rice W; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ bioRxiv; 2023 Feb; ():. PubMed ID: 36865140 [TBL] [Abstract][Full Text] [Related]
23. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers. Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395 [TBL] [Abstract][Full Text] [Related]
24. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185 [No Abstract] [Full Text] [Related]
31. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963 [TBL] [Abstract][Full Text] [Related]
37. Regulation of B Lymphocyte Development by Histone H2A Deubiquitinase BAP1. Lin YH; Liang Y; Wang H; Tung LT; Förster M; Subramani PG; Di Noia JM; Clare S; Langlais D; Nijnik A Front Immunol; 2021; 12():626418. PubMed ID: 33912157 [TBL] [Abstract][Full Text] [Related]
38. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Bott M; Brevet M; Taylor BS; Shimizu S; Ito T; Wang L; Creaney J; Lake RA; Zakowski MF; Reva B; Sander C; Delsite R; Powell S; Zhou Q; Shen R; Olshen A; Rusch V; Ladanyi M Nat Genet; 2011 Jun; 43(7):668-72. PubMed ID: 21642991 [TBL] [Abstract][Full Text] [Related]
39. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX. De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226 [TBL] [Abstract][Full Text] [Related]
40. Somatic alteration and depleted nuclear expression of BAP1 in human esophageal squamous cell carcinoma. Mori T; Sumii M; Fujishima F; Ueno K; Emi M; Nagasaki M; Ishioka C; Chiba N Cancer Sci; 2015 Sep; 106(9):1118-29. PubMed ID: 26081045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]